Tag: NYSE:ABBV

  • Healthcare Active Stocks: AbbVie Inc (NYSE:ABBV), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corporation (NYSE:BSX), Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

    AbbVie Inc (NYSE:ABBV) Chief Executive Richard Gonzalez has pressed the case for his $46 billion pursuit of drugmaker Shire (SHP.L) in discreet meetings with shareholders in London this week and is now weighing his next move, according to people familiar with the matter. AbbVie Inc (NYSE:ABBV) net profit margin is 21.80% and weekly performance is 1.07%. On last trading day company shares ended up $57.40. Analysts mean target price for the company is $62.43. AbbVie Inc (NYSE:ABBV) distance from 50-day simple moving average is 7.01%.

    Bristol-Myers Squibb Co (NYSE:BMY) has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Daklinza (daclatasvir) and Sunvepra (asunaprevir), as a new treatment that can lead to cure for many patients with genotype 1 chronic hepatitis C virus (HCV) infection in Japan. Bristol-Myers Squibb Co (NYSE:BMY) shares advanced 0.89% in last trading session and ended the day on $48.01. BMY Gross Margin is 72.40% and its return on assets is 8.00%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -3.05%.

    Analysts at CRT Capital initiated coverage on shares of Boston Scientific (NYSE:BSX) in a research report issued to clients and investors on Monday. The firm set a “buy” rating and a $16.00 price target on the stock.Boston Scientific Corporation (NYSE:BSX) shares moved up 0.69% in last trading session and was closed at $13.02, while trading in range of $13.01-$13.14. Boston Scientific Corporation (NYSE:BSX) year to date performance is 8.32%.

    Synta Pharmaceuticals Corp. (NASDAQ:SNTA) said it has been notified by the Food and Drug Administration of the agency’s early action granting authorization of Synta’s new drug application for Beleodaq for injection to treat declined or refractory peripheral T-cell lymphoma. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) ended the last trading day at $4.74. Company weekly volatility is calculated as 4.56% and price to cash ratio as 5.61. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) showed a positive weekly performance of 17.04%.